TransCode Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	2.77	4.97	20.83	0.83	0.2
Cash & Cash Equivalents	2.77	4.97	20.83	0.83	0.2
Cash Growth	-44.30%	-76.14%	2415.15%	304.96%	-
Receivables	0	0.36	0	0	0
Other Current Assets	1.69	2.05	1.91	0	0
Total Current Assets	4.46	7.38	22.73	0.83	0.2
Property, Plant & Equipment	0.6	0.21	0.21	0	0
Other Long-Term Assets	0.11	0	0	0.22	0
Total Long-Term Assets	0.71	0.21	0.21	0.22	0
Total Assets	5.17	7.59	22.94	1.06	0.2
Accounts Payable	3.05	4.35	2.5	0.4	0.06
Deferred Revenue	0.03	0	0.03	0	0
Current Debt	0.41	0	0	0	0
Total Current Liabilities	3.49	4.35	2.53	0.4	0.06
Long-Term Debt	0.04	0	0	2.09	0.93
Other Long-Term Liabilities	0	0	0	1.97	0.32
Total Long-Term Liabilities	0.04	0	0	4.06	1.25
Total Liabilities	3.53	4.35	2.53	4.46	1.31
Total Debt	0.45	0	0	2.09	0.93
Debt Growth	-	-	-	124.90%	-
Retained Earnings	-46.42	-27.87	-10.31	-3.46	-1.12
Shareholders' Equity	1.64	3.24	20.4	-3.41	-1.11
Net Cash / Debt	2.32	4.97	20.83	-1.26	-0.72
Net Cash / Debt Growth	-53.36%	-76.14%	-	-	-
Net Cash Per Share	12.94	306.28	1977.39	-217.20	-124.82
Working Capital	0.96	3.03	20.2	0.43	0.14
Book Value Per Share	9.17	199.77	1937.30	-588.11	-191.50

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).